Ferrous Fumarate tab
ApprovedSmall molecule
Ferrous Fumarate tab is one of 34 small molecule programs targeting Iron deficiency anemia. It is currently in Approved.
1
Indications
2
Total Trials
0
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
85 competitors in Iron Deficiency Anemia
#DrugCompanyPhaseTrials
1Injectafer
AAmerican Regent, Inc.
Approved
Feraheme
AAzurity Pharmaceuticals
Approved
Folvite
Eli LillyApproved
Niacor
AbbVieApproved
Venofer
AAmerican Regent, Inc.
Phase 3
Dexferrum
NNew River Pharmaceuticals
Phase 3
Auryxia
KKeryx Biopharmaceuticals
Phase 3
Iron
WWatson Pharmaceuticals
Phase 3
IV Iron
PfizerPhase 3
Standard Medical Care
SSecond Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Iron deficiency anemia2 trials
Lactoferrin With Ferrous Gluconate Versus Ferrous Gluconate in Treatment of Iron Deficiency Anemia During Pregnancy
Completed·—·Phase 4·NCT06252103·40 enrolled
Amino Acid Chelated Iron Versus Ferrous Fumarate in the Treatment of Iron Deficiency Anemia With Pregnancy: Randomized Controlled Trial
Unknown status·—·Phase 4·NCT03830034·150 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ferrous Fumarate tab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- AAin Shams University